Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
CAMBRIDGE, Mass., April 26, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2018.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 6079429. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
